Patryk B.
- Country
- Poland
- Department
- n/a
Research Overview
- A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization
- Evaluation of Baxdrostat and Dapagliflozin on Heart Failure Incidence and Cardiovascular Mortality in High-Risk Patients: A Phase III Randomized Controlled Trial
- Evaluation of Vicadrostat (BI 690517) and Empagliflozin Efficacy and Safety in Patients with Symptomatic Chronic Heart Failure and Reduced Ejection Fraction
Data & Insights
Has run more than one trial at 272 of 791 partner sites.
Specializations
Cardiovascular Medicine
The investigator specializes in preventive cardiology with a particular focus on heart failure prevention and management of cardiovascular risk factors.
- Heart Failure Prevention
- Cardiovascular Risk Management
- Preventive Cardiology
The research interest extends to novel therapeutic approaches in reducing cardiovascular mortality and preventing adverse cardiac events.
Therapeutic Innovation
Working at the forefront of combination therapy research, investigating innovative treatment strategies for cardiovascular disease prevention.
- Combined Treatment Approaches
- Novel Therapeutic Strategies
- Risk Reduction Interventions
The investigator explores therapeutic combinations to enhance cardiovascular outcomes in at-risk populations.
Clinical Outcomes
Focused on investigating cardiovascular mortality reduction and improving outcomes in patients at risk of developing heart failure.
- Mortality Risk Reduction
- Cardiovascular Event Prevention
- Patient Outcome Optimization
The research emphasizes the assessment of therapeutic interventions on cardiovascular health outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.